Orchestra BioMed (OBIO) Competitors $2.75 -0.22 (-7.41%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$2.74 0.00 (-0.18%) As of 05/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OBIO vs. NPCE, SMLR, TCMD, NNOX, STIM, ZIMV, SMTI, SNWV, PDEX, and NVROShould you be buying Orchestra BioMed stock or one of its competitors? The main competitors of Orchestra BioMed include NeuroPace (NPCE), Semler Scientific (SMLR), Tactile Systems Technology (TCMD), Nano-X Imaging (NNOX), Neuronetics (STIM), ZimVie (ZIMV), Sanara MedTech (SMTI), SANUWAVE Health (SNWV), Pro-Dex (PDEX), and Nevro (NVRO). These companies are all part of the "medical equipment" industry. Orchestra BioMed vs. NeuroPace Semler Scientific Tactile Systems Technology Nano-X Imaging Neuronetics ZimVie Sanara MedTech SANUWAVE Health Pro-Dex Nevro Orchestra BioMed (NASDAQ:OBIO) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Does the MarketBeat Community believe in OBIO or NPCE? NeuroPace received 12 more outperform votes than Orchestra BioMed when rated by MarketBeat users. However, 100.00% of users gave Orchestra BioMed an outperform vote while only 60.78% of users gave NeuroPace an outperform vote. CompanyUnderperformOutperformOrchestra BioMedOutperform Votes19100.00% Underperform VotesNo VotesNeuroPaceOutperform Votes3160.78% Underperform Votes2039.22% Which has higher earnings and valuation, OBIO or NPCE? NeuroPace has higher revenue and earnings than Orchestra BioMed. NeuroPace is trading at a lower price-to-earnings ratio than Orchestra BioMed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrchestra BioMed$2.64M39.94-$49.12M-$1.67-1.65NeuroPace$79.91M4.83-$32.96M-$0.95-12.41 Is OBIO or NPCE more profitable? NeuroPace has a net margin of -36.74% compared to Orchestra BioMed's net margin of -2,179.33%. Orchestra BioMed's return on equity of -107.04% beat NeuroPace's return on equity.Company Net Margins Return on Equity Return on Assets Orchestra BioMed-2,179.33% -107.04% -70.88% NeuroPace -36.74%-205.41%-28.29% Do insiders and institutionals hold more shares of OBIO or NPCE? 53.5% of Orchestra BioMed shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 6.7% of Orchestra BioMed shares are held by company insiders. Comparatively, 22.2% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, OBIO or NPCE? Orchestra BioMed has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Do analysts rate OBIO or NPCE? Orchestra BioMed currently has a consensus price target of $15.00, suggesting a potential upside of 445.45%. NeuroPace has a consensus price target of $15.20, suggesting a potential upside of 28.92%. Given Orchestra BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than NeuroPace.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orchestra BioMed 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20NeuroPace 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media prefer OBIO or NPCE? In the previous week, Orchestra BioMed had 3 more articles in the media than NeuroPace. MarketBeat recorded 7 mentions for Orchestra BioMed and 4 mentions for NeuroPace. NeuroPace's average media sentiment score of 1.59 beat Orchestra BioMed's score of 0.58 indicating that NeuroPace is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Orchestra BioMed 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NeuroPace 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryNeuroPace beats Orchestra BioMed on 10 of the 18 factors compared between the two stocks. Get Orchestra BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for OBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBIO vs. The Competition Export to ExcelMetricOrchestra BioMedSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.36M$4.33B$5.53B$7.93BDividend YieldN/A39.93%5.11%4.22%P/E Ratio-1.7130.0322.5118.54Price / Sales39.9455.31397.62103.30Price / CashN/A51.0838.1834.62Price / Book1.456.056.734.25Net Income-$49.12M$68.71M$3.22B$248.18M7 Day Performance-1.08%-0.24%1.38%1.03%1 Month Performance-21.88%-2.90%2.79%2.70%1 Year Performance-50.45%21.00%15.41%4.05% Orchestra BioMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBIOOrchestra BioMed2.7761 of 5 stars$2.75-7.4%$15.00+445.5%-37.5%$105.36M$2.64M-1.714Gap UpHigh Trading VolumeNPCENeuroPace3.8652 of 5 stars$11.62+4.2%$15.20+30.8%-15.6%$380.59M$79.91M-11.62170Upcoming EarningsShort Interest ↓SMLRSemler Scientific3.1065 of 5 stars$35.37-4.0%$71.00+100.7%+27.6%$339.45M$56.29M7.20120Upcoming EarningsGap UpTCMDTactile Systems Technology2.9437 of 5 stars$14.17-2.8%$18.00+27.0%-3.6%$335.35M$292.98M20.24980Upcoming EarningsNNOXNano-X Imaging2.5741 of 5 stars$5.15-1.9%$12.00+133.0%-45.5%$297.56M$11.28M-6.06190STIMNeuronetics1.2688 of 5 stars$4.45-0.7%$5.50+23.6%+25.5%$292.88M$74.89M-3.62180Upcoming EarningsNews CoverageZIMVZimVie2.4826 of 5 stars$9.31-1.4%$19.50+109.5%-41.7%$259.26M$449.75M-0.712,700Positive NewsSMTISanara MedTech2.0254 of 5 stars$31.64-0.3%$48.50+53.3%+3.2%$247.00M$86.67M-31.9660News CoveragePositive NewsSNWVSANUWAVE HealthN/A$27.40-3.8%N/AN/A$234.24M$32.63M-7.0340Positive NewsHigh Trading VolumePDEXPro-Dex1.4247 of 5 stars$69.00+6.3%$52.00-24.6%+261.6%$225.01M$61.00M34.33140Earnings ReportShort Interest ↑News CoverageHigh Trading VolumeNVRONevro0.1892 of 5 stars$5.85+0.1%$5.36-8.3%-43.8%$224.32M$408.52M-3.091,090Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies NPCE Competitors SMLR Competitors TCMD Competitors NNOX Competitors STIM Competitors ZIMV Competitors SMTI Competitors SNWV Competitors PDEX Competitors NVRO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OBIO) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orchestra BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OBIO Stock Free OBIO Stock Alerts